A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
|Podcasts|August 26, 2022
Pharmacy Focus: Psychedelic Pharmacy - The Future of Ketamine
Industry partnerships will be essential to improving access to ketamine, according to expert Kevin Nicholson.
Advertisement
This month, we spoke with Kevin Nicholson, CEO of Ketamine Wellness Centers and recently-announced CEO of Delic Corp., to discuss the future of ketamine research and why industry partnerships will be crucial to improving access.
Advertisement
Related to this article
Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
October’s hematology coverage highlighted first-line pirtobrutinib, questions about myeloma treatment duration and early intervention, and pharmacists’ roles in medication safety and access.
October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.
Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
What Happens Before the First Dose? 5 Steps That Shape Lung Cancer Treatment
3
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
4
Full IDWeek Data Highlights 31-Valent Pneumococcal Conjugate Vaccine Candidate in Adults
5